Literature DB >> 34085260

Construction of Recombinant Cell Lines for GPCR Expression.

Philip J Reeves1.   

Abstract

Large-scale recombinant expression of G protein-coupled receptors (GPCRs) is required for structure and function studies where there is a need for milligram amounts of protein in pure form. Here we describe a procedure for the construction of human embryonic kidney 293S (HEK293S) stable cell lines for inducible expression of the gene encoding bovine rhodopsin. The HEK293S cell line is particularly suitable for this application because of several favorable properties as a recombinant host including: its ease of transfection, its capacity for handling large amounts of protein cargo, and its ability to perform the necessary co- and post-translational modifications required for correct folding and processing of complex membrane proteins such as GPCRs. The procedures described here will focus on the HEK293S GnTI- cell line, an HEK293S derivative that is widely used for the production of glycoproteins modified homogeneously with truncated N-glycans.

Entities:  

Keywords:  Calcium phosphate; Glycosylation; Sodium butyrate; Tetracycline

Year:  2021        PMID: 34085260     DOI: 10.1007/978-1-0716-1221-7_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Expression strategies for structural studies of eukaryotic membrane proteins.

Authors:  Joseph A Lyons; Azadeh Shahsavar; Peter Aasted Paulsen; Bjørn Panyella Pedersen; Poul Nissen
Journal:  Curr Opin Struct Biol       Date:  2016-06-27       Impact factor: 6.809

2.  N-glycosylation of human acetylcholinesterase: effects on activity, stability and biosynthesis.

Authors:  B Velan; C Kronman; A Ordentlich; Y Flashner; M Leitner; S Cohen; A Shafferman
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

Review 3.  Large-scale production and protein engineering of G protein-coupled receptors for structural studies.

Authors:  Dalibor Milić; Dmitry B Veprintsev
Journal:  Front Pharmacol       Date:  2015-03-31       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.